The Asia Pacific biopsy devices market size reached US$ 410.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 821.3 Million by 2032, exhibiting a growth rate (CAGR) of 7.77% during 2024-2032.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 410.5 Million |
Market Forecast in 2032
|
US$ 821.3 Million |
Market Growth Rate (2024-2032) | 7.77% |
Biopsy devices are surgical equipment used to remove tissues from different organs. They are utilized by medical practitioners, surgeons, cardiologists, and radiologists to diagnose the presence of cancerous diseases. Some of the commonly used biopsy devices include aspiration needles, localization wires, and forceps. At present, biopsy devices are employed in medical clinics, hospitals, and diagnostic centers across the Asia Pacific region.
The increasing prevalence of cancer, along with rising initiatives for generating awareness about cancer screening programs, represents one of the significant factors driving the biopsy devices market in the Asia Pacific region. Moreover, the growing risks of infection due to improper care of invasive biopsy wounds have resulted in the introduction of stringent healthcare guidelines, which has further strengthened the market growth. Apart from this, rapid urbanization, in confluence with increasing technological advancements, is creating a positive impact on the market. However, the sudden outbreak of the coronavirus disease (COVID-19) has negatively affected the biopsy devices market as the focus of the healthcare personnel has presently shifted towards the treatment of COVID-19 patients. The market is projected to experience growth once the pandemic situation comes under control.
IMARC Group provides an analysis of the key trends in each segment of the Asia Pacific biopsy devices market report, along with forecasts at the regional and country levels from 2024-2032. Our report has categorized the market based on procedure type, product, application, guidance technique and end user.
Breakup by Procedure Type:
Breakup by Product:
Breakup by Application:
Breakup by Guidance Technique:
Breakup by End User:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Million |
Segment Coverage | Procedure Type, Product, Application, Guidance Technique, End User, Country |
Countries Covered | China, Japan, India, South Korea, Australia, Indonesia, Others |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The Asia Pacific biopsy devices market was valued at US$ 410.5 Million in 2023.
We expect the Asia Pacific biopsy devices market to exhibit a CAGR of 7.77% during 2024-2032.
The growing adoption of biopsy devices by radiologists, surgeons, cardiologists, and other medical practitioners to diagnose the presence or extent of diseases that are cancerous or inflammatory in nature, is primarily driving the Asia Pacific biopsy devices market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of various elective cancer treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the Asia Pacific market for biopsy devices.
Based on the procedure type, the Asia Pacific biopsy devices market can be segmented into surgical biopsy and needle biopsy, where needle biopsy holds the majority of the total market share.
Based on the product, the Asia Pacific biopsy devices market has been divided into biopsy guidance systems, needle based biopsy guns, biopsy needles, biopsy forceps, and others. Among these, needle based biopsy guns currently exhibit a clear dominance in the market.
Based on the application, the Asia Pacific biopsy devices market can be categorized into breast biopsy, lung biopsy, colorectal biopsy, prostate biopsy, and others. Currently, breast biopsy accounts for the majority of the total market share.
Based on the guidance technique, the Asia Pacific biopsy devices market has been segregated into ultrasound-guided biopsy, stereotactic-guided biopsy, MRI-guided biopsy, and others. Among these, MRI-guided biopsy currently exhibits a clear dominance in the market.
Based on the end user, the Asia Pacific biopsy devices market can be bifurcated into hospitals and clinics, academic and research institutes, and others. Currently, hospitals and clinics hold the largest market share.
On a regional level, the market has been classified into China, Japan, India, South Korea, Australia, Indonesia, and others, where China currently dominates the Asia Pacific biopsy devices market.